March 27, 2018 / 11:24 AM / 8 months ago

BRIEF-U.S. FDA Accepts Bristol-Myers Squibb's Application For Opdivo Plus Yervoy

March 27 (Reuters) - Bristol-Myers Squibb Co:

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC COLORECTAL CANCER FOR PRIORITY REVIEW

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC COLORECTAL CANCER FOR PRIORITY REVIEW

* BRISTOL-MYERS SQUIBB CO - ‍FDA ALSO GRANTED OPDIVO PLUS YERVOY COMBINATION BREAKTHROUGH THERAPY DESIGNATION FOR THIS POTENTIAL INDICATION​

* BRISTOL-MYERS SQUIBB CO - FDA ACTION DATE FOR FURTHER REGULATION ON THE SBLA IS JULY 10, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below